keyword
https://read.qxmd.com/read/38536540/palbociclib-inhibits-the-progression-of-head-and-neck-cancer-and-improves-the-cetuximab-response-under-specific-condition-in-vitro-and-in-vivo
#1
JOURNAL ARTICLE
Ruichen Li, Qi Wang, Yang Zhao, Yi Zhu, Xiaoshen Wang
BACKGROUND: In head and neck squamous cell carcinoma (HNSCC) with human papillomavirus (HPV)-negative, deregulation of cell cycle is partly due to inactivation of p16INK4 and overexpression of cyclin D1. Here we investigated the in vitro and in vivo effects of the CDK4/6 inhibitor Palbociclib alone or combined with EGFR inhibitor Cetuximab in HNSCC. METHODS AND RESULTS: CCK-8, soft agar assay, colony formation assay, wound healing assay and transwell assay, β-galactosidase assay, western blotting, and cell-derived xenografts were used to investigated the in vitro and in vivo activity of drugs...
March 27, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38527281/brigatinib-combined-with-cetuximab-in-the-fifth-line-treatment-of-non-small-cell-lung-cancer-with-egfr-p-c797s-mutation-in-critically-ill-patients-a-report-of-two-cases-and-literature-review
#2
JOURNAL ARTICLE
Juanjuan Liu, Hongtao Lei, Ding Zhang, Ning Zhang
For critically ill patients with non-small cell lung cancer (NSCLC) in need of life-saving treatment, there is currently no reported evidence regarding the use of medication specifically targeting epidermal growth factor receptor (EGFR) p.C797S mutation, which is known to cause resistance to third-generation tyrosine kinase inhibitors (TKIs). Our report aims to investigate and explore treatment strategies to overcome resistance associated with EGFR p.C797S mutation in order to provide potential therapeutic options for these patients...
March 15, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38526722/structure-guided-and-phage-assisted-evolution-of-therapeutic-antibodies-to-reverse-on-target-point-mutation-mediated-resistance
#3
JOURNAL ARTICLE
Xinlei Zhuang, Shuqing Chen, Liqiang Pan
Resistance to therapeutic antibodies caused by on-target point mutations is a major obstacle in anticancer therapy, creating an "unmet clinical need." To tackle this problem, researchers are developing new generations of antibody drugs that can overcome the resistance mechanisms of existing agents. We have previously reported a structure-guided and phage-assisted evolution (SGAPAE) approach to evolve cetuximab, a therapeutic antibody, to effectively reverse the resistance driven by EGFRS492R or EGFRG465R mutations, without changing the binding epitope or compromising the antibody efficacy...
2024: Methods in Molecular Biology
https://read.qxmd.com/read/38525371/efficacy-and-safety-of-maintenance-therapy-using-cetuximab-in-patients-with-metastatic-colorectal-cancer-retrospective-study
#4
JOURNAL ARTICLE
Tiantian Xuan, Zhanmei Wang, Sibo Meng, Jiaxin Li, Jisheng Li, Fangli Cao, Linli Qu
PURPOSE: Cetuximab (CET) combined with chemotherapy significantly improved the survival in RAS and RAF wild-type metastatic colorectal cancer (mCRC) patients, while clinical evidence was lacking on the use of maintenance therapy (MT). The study aimed to explore the role of maintenance therapy following Cetuximab + chemotherapy and the optimal Cetuximab-based maintenance therapy regimen. PATIENTS AND METHODS: We retrospectively reviewed data on the efficacy and safety of CET-based MT in patients with mCRC who achieved disease control after induction therapy...
2024: Cancer Management and Research
https://read.qxmd.com/read/38515460/anti-eno1-antibody-combined-with-metformin-against-tumor-resistance-a-novel-antibody-based-platform
#5
JOURNAL ARTICLE
Xiong Shu, Hui Wen Zhang, Shi Ya Liu, Li Xin Sun, Tao Zhang, Yu Liang Ran
BACKGROUND: Antibody-based platforms ( i.e. , ADC) have emerged as one of the most encouraging tools for the cancer resistance caused by cancer stem cells (CSCs) enrichment. Our study might provide a promising therapeutic direction against drug resistance and serve as a potential precursor platform for screening ADC. METHODS: The cell migration, invasion, drug resistance, and self-renewal were assessed by the cell invasion and migration assay, wound healing assay, CCK-8 assay, colony formation assay, and sphere formation assay, respectively...
2024: PeerJ
https://read.qxmd.com/read/38514766/nivolumab-plus-ipilimumab-versus-the-extreme-regimen-in-recurrent-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-a-cost-effectiveness-analysis
#6
JOURNAL ARTICLE
Dongmei Ye, Xueyan Liang, Xiaoyu Chen, Yan Li
In the CheckMate 651 study, nivolumab plus ipilimumab versus EXTREME (cisplatin/carboplatin + cetuximab + fluorouracil) regimen was compared for effectiveness. It is not known whether these immunotherapy agents are cost-effective for recurrent or metastatic squamous cell carcinomas of the head and neck (R/M SCCHN). The purpose of this study was to compare the cost-effectiveness of nivolumab plus ipilimumab with EXTREME in the first-line setting from the standpoint of third-party payers in the United States...
March 21, 2024: Scientific Reports
https://read.qxmd.com/read/38510242/antibody-dependent-cellular-cytotoxicity-inducing-anti-egfr-antibodies-as-effective-therapeutic-option-for-cutaneous-melanoma-resistant-to-braf-inhibitors
#7
JOURNAL ARTICLE
Elena Muraro, Barbara Montico, Benedict Lum, Francesca Colizzi, Giorgio Giurato, Annamaria Salvati, Roberto Guerrieri, Aurora Rizzo, Elisa Comaro, Vincenzo Canzonieri, Andrea Anichini, Michele Del Vecchio, Roberta Mortarini, Massimo Milione, Alessandro Weisz, Maria Antonietta Pizzichetta, Fiona Simpson, Riccardo Dolcetti, Elisabetta Fratta, Luca Sigalotti
INTRODUCTION: About 50% of cutaneous melanoma (CM) patients present activating BRAF mutations that can be effectively targeted by BRAF inhibitors (BRAFi). However, 20% of CM patients exhibit intrinsic drug resistance to BRAFi, while most of the others develop adaptive resistance over time. The mechanisms involved in BRAFi resistance are disparate and globally seem to rewire the cellular signaling profile by up-regulating different receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38503018/dynamic-ctdna-based-analysis-of-drug-resistant-gene-alterations-at-ras-braf-wild-type-metastatic-colorectal-cancer-patients-after-cetuximab-plus-chemotherapy-as-the-first-line-treatment
#8
JOURNAL ARTICLE
Yu-Wen Zhou, Xin Zhao, Lu Ni, Peng Cao, Wei-Bing Leng, Qing Zhu, Hong-Feng Gou, Jiao Zhang, Xiao-Fen Li, Meng Qiu
BACKGROUND: The purpose of this study was to explore the dynamic changes of genomic mutations and their correlations with the efficacy in metastatic colorectal cancer (mCRC) patients treated with cetuximab plus mFOLFOX as the first-line treatment. METHODS: We included mCRC patients from January 2018 to October 2020 as a studied cohort which were treated with cetuximab plus mFOLFOX as first line therapy. Blood samples were collected for circulating tumor DNA (ctDNA) test at three timepoints: before the first-line therapy(baseline), at the time of first-line progression and at the time of second-line progression...
March 18, 2024: International Immunopharmacology
https://read.qxmd.com/read/38500712/a-case-of-photoimmunotherapy-for-nasopharyngeal-carcinoma-requiring-emergency-tracheostomy
#9
Yukiomi Kushihashi, Tatsuo Masubuchi, Isaku Okamoto, Chihiro Fushimi, Morio Yamazaki, Hisashi Asano, Reo Aoki, Shota Fujii, Yukiko Asako, Yuichiro Tada
INTRODUCTION: Photoimmunotherapy (PIT) is a treatment wherein intravenous cetuximab sarotalocan sodium is administered followed by laser light irradiation. This treatment exhibits a specific antitumor effect if in tumors expressing the epidermal growth factor receptor, regardless of the carcinoma [Mitsunaga et al.: Nat Med. 2011;17(12):1685-91, Sato et al.: ACS Cent Sci. 2018;4(11):1559-69, Nakajima et al.: Cancer Sci. 2018;109(9):2889-96]. The current indications are unresectable, locally advanced, or locally recurrent head and neck cancer...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38500295/neoadjuvant-chemotherapy-alone-or-combined-with-egfr-directed-targeted-therapy-or-anti-pd-1-immunotherapy-for-locally-advanced-lacrimal-sac-and-nasolacrimal-duct-carcinomas
#10
JOURNAL ARTICLE
Jeremy Goldfarb, Janet Fan, Luana Guimaraes de Sousa, Neal Akhave, Jeffrey Myers, Ryan Goepfert, Krish Manisundaram, Jiawei Zhao, Steven J Frank, Amy Moreno, Renata Ferrarotto, Bita Esmaeli
BACKGROUND/AIMS: We describe our findings in patients with locally advanced lacrimal sac and nasolacrimal duct (NLD) carcinoma who received neoadjuvant systemic therapy. METHODS: We identified patients with locally advanced primary lacrimal sac/NLD carcinoma treated with neoadjuvant systemic intravenous therapy at our institution during 2017-2019. RESULTS: The study included seven patients, four men and three women; the mean age was 60.4 years (range: 43-76)...
March 18, 2024: Seminars in Ophthalmology
https://read.qxmd.com/read/38494955/antibody-epitope-conjugates-deliver-immunogenic-t-cell-epitopes-more-efficiently-when-close-to-cell-surfaces
#11
JOURNAL ARTICLE
W van der Wulp, W Luu, M E Ressing, J Schuurman, S I van Kasteren, L Guelen, R C Hoeben, B Bleijlevens, M H M Heemskerk
Antibody-mediated delivery of immunogenic viral CD8+ T-cell epitopes to redirect virus-specific T cells toward cancer cells is a promising new therapeutic avenue to increase the immunogenicity of tumors. Multiple strategies for viral epitope delivery have been shown to be effective. So far, most of these have relied on a free C-terminus of the immunogenic epitope for extracellular delivery. Here, we demonstrate that antibody-epitope conjugates (AECs) with genetically fused epitopes to the N-terminus of the antibody can also sensitize tumors for attack by virus-specific CD8+ T cells...
2024: MAbs
https://read.qxmd.com/read/38494826/-a-case-of-severe-skin-disorder-during-pembrolizumab-treatment-for-recurrent-maxillary-gingival-carcinoma
#12
JOURNAL ARTICLE
Satoe Okuma, Masaaki Karino, Yuhei Matsuda, Hiroto Tatsumi, Tatsuo Okui, Takahiro Kanno
Immune checkpoint inhibitors are known to produce immune-related adverse events(irAE)that require medical management. Herein, we report a case of a patient treated with pembrolizumab who experienced a Grade 3 interrupted skin disorder. The patient is a 67-year-old female diagnosed with right maxillary gingival squamous cell carcinoma(cT4aN0M0, Stage ⅣA)and underwent partial right maxillectomy, right extended supra-omohyoid neck dissection, and maxillary reconstruction using a forearm flap. Six months postoperatively, late lymph node metastases with extracapsular spread was found in the right buccal lymph node and the left neck, and the patient underwent right buccal lymphadenectomy and left modified radical neck dissection...
March 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38494151/biodistribution-and-therapeutic-efficacy-of-a-gold-nanoparticle-based-targeted-drug-delivery-system-against-pancreatic-cancer
#13
JOURNAL ARTICLE
Chandra Kumar Elechalawar, Suresh Kumar Gulla, Ram Vinod Roy, Nicolas Means, Yushan Zhang, Sima Asifa, David J Robertson, Chao Xu, Resham Bhattacharya, Priyabrata Mukherjee
Pancreatic cancer is characterized by desmoplasia; crosstalk between pancreatic cancer cells (PCCs) and pancreatic stellate cells (PSCs) leads to the deposition of extracellular matrix proteins in the tumor environment resulting in poor vascularity. Targeting either PCCs or PSCs individually has produced mixed results, and there is currently no effective strategy to target both cell types simultaneously. Previously, we demonstrated, through in vitro cell culture experiments, that a specific gold nanoparticle-based nanoformulation containing the anti-EGFR antibody cetuximab (C225) as a targeting agent and gemcitabine as a chemotherapeutic agent effectively targets both PCCs and PSCs simultaneously...
March 15, 2024: Cancer Letters
https://read.qxmd.com/read/38475023/near-infrared-fluorescence-imaging-sensor-with-laser-diffuser-for-visualizing-photoimmunotherapy-effects-under-endoscopy
#14
JOURNAL ARTICLE
Toshihiro Takamatsu, Hideki Tanaka, Tomonori Yano
The drug efficacy evaluation of tumor-selective photosensitive substances was expected to be enabled by imaging the fluorescence intensity in the tumor area. However, fluorescence observation is difficult during treatments that are performed during gastrointestinal endoscopy because of the challenges associated with including the fluorescence filter in the camera part. To address this issue, this study developed a device that integrates a narrow camera and a laser diffuser to enable fluorescence imaging through a forceps port...
February 25, 2024: Sensors
https://read.qxmd.com/read/38467828/inhibition-of-the-aurka-yap1-axis-is-a-promising-therapeutic-option-for-overcoming-cetuximab-resistance-in-colorectal-cancer-stem-cells
#15
JOURNAL ARTICLE
Anxo Rio-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
BACKGROUND: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/RAF. YAP1 activation is associated with this resistance, prompting an investigation into AURKA's role in mediating YAP1 phosphorylation at Ser397, as observed in breast cancer. METHODS: We used transcriptomic analysis along with in vitro and in vivo models of RAS/RAF wild-type CRC to study YAP1 Ser397 phosphorylation as a potential biomarker for cetuximab resistance...
March 11, 2024: British Journal of Cancer
https://read.qxmd.com/read/38460391/what-factors-contribute-to-cancer-survivors-self-management-skills-a-cross-sectional-observational-study
#16
JOURNAL ARTICLE
Janet M J Been-Dahmen, Heleen van der Stege, Wendy H Oldenmenger, Cora Braat, Mariska C M van der Lans, Mark Scheper, AnneLoes van Staa, Erwin Ista
PURPOSE: Many cancer survivors, facing the consequences of their disease and its treatment, have medical and supportive aftercare needs. However, limited knowledge exists regarding the relationship between support needs and survivors' self-management skills. The study aim is to explore factors contributing to cancer survivors' self-management skills. METHODS: A cross-sectional study was conducted among cancer survivors (n = 277) of two outpatient oncology clinics at a university hospital in the Netherlands...
February 23, 2024: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://read.qxmd.com/read/38459120/single-cell-landscape-of-undifferentiated-pleomorphic-sarcoma
#17
JOURNAL ARTICLE
Yifei Lu, Deqian Chen, Bingnan Wang, Wenjun Chai, Mingxia Yan, Yong Chen, Yong Zhan, Ran Yang, Enqing Zhou, Shuyang Dai, Yi Li, Rui Dong, Biqiang Zheng
Undifferentiated pleomorphic sarcoma (UPS) is a highly aggressive malignant soft tissue tumor with a poor prognosis; however, the identity and heterogeneity of tumor populations remain elusive. Here, eight major cell clusters were identified through the RNA sequencing of 79,569 individual cells of UPS. UPS originates from mesenchymal stem cells (MSCs) and features undifferentiated subclusters. UPS subclusters were predicted to exist in two bulk RNA datasets, and had a prognostic value in The Cancer Genome Atlas (TCGA) dataset...
March 8, 2024: Oncogene
https://read.qxmd.com/read/38458639/final-results-of-urelumab-an-anti-cd137-agonist-monoclonal-antibody-in-combination-with-cetuximab-or-nivolumab-in-patients-with-advanced-solid-tumors
#18
JOURNAL ARTICLE
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason J Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
BACKGROUND: Resistance to immune checkpoint inhibitors and targeted treatments for cancer is common; thus, novel immunotherapy agents are needed. Urelumab is a monoclonal antibody agonist that binds to CD137 receptors expressed on T cells. Here, we report two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors. METHODS: CA186-018: Patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated in a dose-evaluation phase with urelumab 0...
March 7, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38457761/-her2-gene-expression-levels-are-predictive-and-prognostic-in-patients-with-metastatic-colorectal-cancer-enrolled-in-calgb-swog-80405
#19
JOURNAL ARTICLE
Francesca Battaglin, Fang-Shu Ou, Xueping Qu, Howard S Hochster, Donna Niedzwiecki, Richard M Goldberg, Robert J Mayer, Karam Ashouri, Tyler J Zemla, Charles D Blanke, Alan P Venook, Omar Kabbarah, Heinz-Josef Lenz, Federico Innocenti
PURPOSE: The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS: Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx)...
March 8, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38457195/early-recurrence-time-to-recurrence-and-recurrence-patterns-assessing-their-impact-on-survival-outcomes-in-head-and-neck-squamous-cell-carcinoma-r-m-hnscc-patients-treated-with-first-line-platinum-based-chemotherapy
#20
JOURNAL ARTICLE
Pasvich Pitakpaiboonkul, Chuleeporn Jiarpinitnun, Poompis Pattaranutaporn, Nuttapong Ngamphaiboon
BACKGROUND: R/M-HNSCC patients typically receive 1L platinum-based chemotherapy with pembrolizumab or cetuximab. However, the outcomes for patients with early recurrence (<6 months) remain unclear due to their exclusion from most 1L studies. This study aimed to assess the impact of time-to-recurrence intervals (TTRI) and recurrence patterns on the survival of R/M-HNSCC patients. METHODS: We identified non-curable R/M-HNSCC patients at our institution from 1/2008 through 6/2020...
February 2024: Cancer Medicine
keyword
keyword
6842
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.